Please assess the completion status of the following clinical trial:

Trial Title: The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Age ≥ 18 years~2. Newly diagnosed, AL amyloidosis treatment naïve~3. Bone marrow consistent with plasma cell dyscrasia~4. Confirmed diagnosis of AL amyloidosis~5. Cardiac involvement~6. Planned first-line chemotherapy contains a proteasome-inhibiting agent administered weekly~7. Adequate bone marrow reserve, hepatic and renal function~Key Exclusion Criteria:~1. Non-AL amyloidosis~2. Meets diagnostic criteria for symptomatic multiple myeloma~3. Subject is eligible for and plans to undergo ASCT~4. History of Grade ≥ 3 infusion-associated AEs or hypersensitivity to another monoclonal antibody, or known hypersensitivity to diphenhydramine or acetaminophen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NEOD001 (Type: EXPERIMENTAL): 24 mg/kg (maximum dose of 2500 mg) of NEOD001 administered once every 28 days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered as a 250 mL bag of normal saline once every 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).